Your browser doesn't support javascript.
loading
Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays.
Whiteaker, Jeffrey R; Halusa, Goran N; Hoofnagle, Andrew N; Sharma, Vagisha; MacLean, Brendan; Yan, Ping; Wrobel, John A; Kennedy, Jacob; Mani, D R; Zimmerman, Lisa J; Meyer, Matthew R; Mesri, Mehdi; Boja, Emily; Carr, Steven A; Chan, Daniel W; Chen, Xian; Chen, Jing; Davies, Sherri R; Ellis, Matthew J C; Fenyö, David; Hiltke, Tara; Ketchum, Karen A; Kinsinger, Chris; Kuhn, Eric; Liebler, Daniel C; Liu, Tao; Loss, Michael; MacCoss, Michael J; Qian, Wei-Jun; Rivers, Robert; Rodland, Karin D; Ruggles, Kelly V; Scott, Mitchell G; Smith, Richard D; Thomas, Stefani; Townsend, R Reid; Whiteley, Gordon; Wu, Chaochao; Zhang, Hui; Zhang, Zhen; Rodriguez, Henry; Paulovich, Amanda G.
Afiliação
  • Whiteaker JR; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue, N., Seattle, WA, 98109, USA.
  • Halusa GN; Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, USA.
  • Hoofnagle AN; Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.
  • Sharma V; Department of Genome Sciences, University of Washington, Seattle, WA, USA.
  • MacLean B; Department of Genome Sciences, University of Washington, Seattle, WA, USA.
  • Yan P; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue, N., Seattle, WA, 98109, USA.
  • Wrobel JA; Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
  • Kennedy J; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue, N., Seattle, WA, 98109, USA.
  • Mani DR; Broad Institute, Cambridge, MA, USA.
  • Zimmerman LJ; Department of Biochemistry, Jim Ayers Institute for Precancer Detection & Diagnosis, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Meyer MR; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Mesri M; Office of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD, USA.
  • Boja E; Office of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD, USA.
  • Carr SA; Broad Institute, Cambridge, MA, USA.
  • Chan DW; Clinical Chemistry Division, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Chen X; Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
  • Chen J; Clinical Chemistry Division, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Davies SR; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Ellis MJ; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Fenyö D; Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, USA.
  • Hiltke T; Office of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD, USA.
  • Ketchum KA; Data Coordinating Center, ESAC, Inc., Rockville, MD, USA.
  • Kinsinger C; Office of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD, USA.
  • Kuhn E; Broad Institute, Cambridge, MA, USA.
  • Liebler DC; Department of Biochemistry, Jim Ayers Institute for Precancer Detection & Diagnosis, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Liu T; Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.
  • Loss M; Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, USA.
  • MacCoss MJ; Department of Genome Sciences, University of Washington, Seattle, WA, USA.
  • Qian WJ; Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.
  • Rivers R; Office of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD, USA.
  • Rodland KD; Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.
  • Ruggles KV; Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, USA.
  • Scott MG; Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Smith RD; Biological Sciences Division and Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA, USA.
  • Thomas S; Clinical Chemistry Division, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Townsend RR; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Whiteley G; Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, USA.
  • Wu C; Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.
  • Zhang H; Clinical Chemistry Division, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Zhang Z; Clinical Chemistry Division, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Rodriguez H; Office of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD, USA.
  • Paulovich AG; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue, N., Seattle, WA, 98109, USA. apaulovi@fredhutch.org.
Methods Mol Biol ; 1410: 223-36, 2016.
Article em En | MEDLINE | ID: mdl-26867747
ABSTRACT
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI) has launched an Assay Portal (http//assays.cancer.gov) to serve as an open-source repository of well-characterized targeted proteomic assays. The portal is designed to curate and disseminate highly characterized, targeted mass spectrometry (MS)-based assays by providing detailed assay performance characterization data, standard operating procedures, and access to reagents. Assay content is accessed via the portal through queries to find assays targeting proteins associated with specific cellular pathways, protein complexes, or specific chromosomal regions. The position of the peptide analytes for which there are available assays are mapped relative to other features of interest in the protein, such as sequence domains, isoforms, single nucleotide polymorphisms, and posttranslational modifications. The overarching goals are to enable robust quantification of all human proteins and to standardize the quantification of targeted MS-based assays to ultimately enable harmonization of results over time and across laboratories.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteômica Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteômica Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article